Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18–59 years) adults-Reference-Cited by-同舟云学术

Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18–59 years) adults

Published:2021-01 Issue: Volume:169 Page:106478
ISSN:0920-1211
Container-title:Epilepsy Research
language:en
Short-container-title:Epilepsy Research

Author:

Andermann Eva,Rosenfeld William,Penovich Patricia^ORCID,Rogin Joanne,Cendes Fernando,Carreño Mar^ORCID,Ramsay R. Eugene,Ben-Menachem Elinor,Gama Helena,Rocha Francisco,Soares-da-Silva Patrício,Tosiello Robert,Blum David^ORCID,Grinnell Todd

Funder

Sunovion

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference18 articles.

1. Epilepsy in the elderly: special considerations and challenges;Acharya;Ann. Indian Acad. Neurol.,2014

2. Full Prescribing Information;Aptiom® (eslicarbazepine acetate),2019

3. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy;Ben-Menachem;Epilepsy Res.,2010

4. Increased risk of stroke and myocardial infarction in patients with epilepsy: a systematic review of population-based cohort studies;Brigo;Epilepsy Behav.,2020

5. Safety, tolerability and efficacy of eslicarbazepine acetate as adjunctive therapy in patients aged ≥65 years with focal seizures;Costa;Drugs Aging,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perampanel as only add-on epilepsy treatment in elderly: A subgroup analysis of real-world data from retrospective, multicenter, observational study;Journal of the Neurological Sciences;2023-12

2. Anti-epileptic medications;Side Effects of Drugs Annual;2022

3. Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience;Drug Safety;2021-09-18